Adverts

Open Access Articles- Top Results for Zonampanel

Zonampanel

</th></tr>
Zonampanel
File:Zonampanel.svg
Systematic (IUPAC) name
[7-(1H-Imidazol-1-yl)-6-nitro-2,3-dioxo-3,4-dihydro-1(2H)-quinoxalinyl]acetic acid
Clinical data
Identifiers
210245-80-0
None
PubChem CID 148200
ChemSpider 130649
Chemical data
Formula C13H9N5O6
331.241 g/mol

Zonampanel (INN, code name YM872) is a quinoxalinedione derivative drug and competitive antagonist of the AMPA receptor which was being investigated by Yamanouchi/Astellas Pharma as a neuroprotective drug for the treatment of ischemic stroke but never completed clinical trials.[1][2][3][4] In clinical trials, zonampanel produced severe side effects including hallucinations, agitation, and catatonia in patients, and this may have been involved in the early termination of the trials.[5]

See also

References

  1. ^ Kewal K. Jain (14 February 2011). The Handbook of Neuroprotection. Springer Science & Business Media. pp. 154–. ISBN 978-1-61779-049-2. 
  2. ^ Arunabha Ray, Kavita Gulati (1 January 2007). Current Trends in Pharmacology. I. K. International Pvt Ltd. pp. 321–. ISBN 978-81-88237-77-7. 
  3. ^ Stephen Waxman (27 May 2005). Multiple Sclerosis As A Neuronal Disease. Academic Press. pp. 245–. ISBN 978-0-08-048941-4. 
  4. ^ Santokh Gill; Olga Pulido (31 January 2007). Glutamate Receptors in Peripheral Tissue: Excitatory Transmission Outside the CNS. Springer Science & Business Media. pp. 37–. ISBN 978-0-306-48644-9. 
  5. ^ Akhlaq A. Farooqui (2 September 2010). Neurochemical Aspects of Neurotraumatic and Neurodegenerative Diseases. Springer Science & Business Media. pp. 73–. ISBN 978-1-4419-6652-0. 



Lua error in package.lua at line 80: module 'Module:Buffer' not found.